Mydriasis Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Mydriasis pipeline constitutes 3+ key companies continuously working towards developing 3+ Mydriasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Mydriasis Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/mydriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mydriasis Market.

The Mydriasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Mydriasis Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Mydriasis treatment therapies with a considerable amount of success over the years.

*
Mydriasis companies working in the treatment market are Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd, and others, are developing therapies for the Mydriasis treatment

*
Emerging Mydriasis therapies in the different phases of clinical trials are- RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others are expected to have a significant impact on the Mydriasis market in the coming years.

*
In September 2024, Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies for retinal and refractive eye disorders, announced the publication of full results from two pivotal Phase 3 trials (MIRA-2 and MIRA-3) in the peer-reviewed journal Ophthalmology. The trials evaluated the safety and efficacy of RYZUMVI Trademark (Phentolamine Ophthalmic Solution 0.75%) for treating pharmacologically-induced mydriasis. The results showed that Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist, effectively reversed pupil dilation with a favorable safety profile.

Mydriasis Overview

Mydriasis is the medical term for the dilation of the pupils, often beyond their normal size, which can occur due to various factors. It can result from physiological responses to low light, emotional arousal, or the use of certain medications like anticholinergics and sympathomimetics. Mydriasis can also indicate underlying medical conditions such as brain injury, drug intoxication, or neurological disorders. Unlike normal pupil dilation, mydriasis is not always responsive to light changes, making it a clinical sign that may require further evaluation.

Get a Free Sample PDF Report to know more about Mydriasis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/mydriasis-pipeline-insight [https://www.delveinsight.com/report-store/mydriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Mydriasis Drugs Under Different Phases of Clinical Development Include:

*
RYZUMVI (Phentolamine Ophthalmic Solution 0.75%): Viatris/Ocuphire Pharma

*
MYDCOMBI: Eyenovia

*
OMIDRIA: Rayner Surgical/Omeros

*
MydCombi: Eyenovia Inc.

*
CTO0303-A: Taejoon Pharmaceutical Co., Ltd.

Mydriasis Route of Administration

Mydriasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Mydriasis Molecule Type

Mydriasis Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Mydriasis Pipeline Therapeutics Assessment

*
Mydriasis Assessment by Product Type

*
Mydriasis By Stage and Product Type

*
Mydriasis Assessment by Route of Administration

*
Mydriasis By Stage and Route of Administration

*
Mydriasis Assessment by Molecule Type

*
Mydriasis by Stage and Molecule Type

DelveInsight's Mydriasis Report covers around 3+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Mydriasis product details are provided in the report. Download the Mydriasis pipeline report to learn more about the emerging Mydriasis therapies [https://www.delveinsight.com/sample-request/mydriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Mydriasis Therapeutics Market include:

Key companies developing therapies for Mydriasis are - Ocuphire Pharma, Thea Laboratories, Omeros Corporation, and others.

Mydriasis Pipeline Analysis:

The Mydriasis pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Mydriasis with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mydriasis Treatment.

*
Mydriasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Mydriasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mydriasis market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Mydriasis drugs and therapies [https://www.delveinsight.com/sample-request/mydriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Mydriasis Pipeline Market Drivers

*
Increasing Prevalence of Eye Conditions, Technological Advancements, Aging Population, Increased Awareness of Eye Health, Surge in Ophthalmic Surgeries, are some of the important factors that are fueling the Mydriasis Market.

Mydriasis Pipeline Market Barriers

*
However, High Cost of Treatment, Side Effects of Mydriatic Agents, Limited Availability in Low-Resource Settings, Competition from Alternative Therapies, Stringent Regulatory Approval, and other factors are creating obstacles in the Mydriasis Market growth.

Scope of Mydriasis Pipeline Drug Insight

*
Coverage: Global

*
Key Mydriasis Companies: Viatris/Ocuphire Pharma, Eyenovia, Rayner Surgical/Omeros, Eyenovia Inc., Taejoon Pharmaceutical Co., Ltd, and others

*
Key Mydriasis Therapies: RYZUMVI (Phentolamine Ophthalmic Solution 0.75%), MYDCOMBI, OMIDRIA, MydCombi, CTO0303-A, and others

*
Mydriasis Therapeutic Assessment: Mydriasis current marketed and Mydriasis emerging therapies

*
Mydriasis Market Dynamics: Mydriasis market drivers and Mydriasis market barriers

Request for Sample PDF Report for Mydriasis Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/mydriasis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Mydriasis Report Introduction

2. Mydriasis Executive Summary

3. Mydriasis Overview

4. Mydriasis- Analytical Perspective In-depth Commercial Assessment

5. Mydriasis Pipeline Therapeutics

6. Mydriasis Late Stage Products (Phase II/III)

7. Mydriasis Mid Stage Products (Phase II)

8. Mydriasis Early Stage Products (Phase I)

9. Mydriasis Preclinical Stage Products

10. Mydriasis Therapeutics Assessment

11. Mydriasis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Mydriasis Key Companies

14. Mydriasis Key Products

15. Mydriasis Unmet Needs

16 . Mydriasis Market Drivers and Barriers

17. Mydriasis Future Perspectives and Conclusion

18. Mydriasis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mydriasis-pipeline-2024-clinical-trials-assessment-fda-approvals-therapies-and-key-companies-involved-by-delveinsight-viatrisocuphire-pharma-eyenovia-rayner-surgicalomeros-eyenovia-inc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.